271 related articles for article (PubMed ID: 21047202)
1. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients.
Wang P; Mao Y; Razo J; Zhou X; Wong ST; Patel S; Elliott E; Shea E; Wu AH; Gaber AO
Pharmacogenomics; 2010 Oct; 11(10):1389-402. PubMed ID: 21047202
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
3. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.
Tang HL; Xie HG; Yao Y; Hu YF
Pharmacogenet Genomics; 2011 Nov; 21(11):713-20. PubMed ID: 21886016
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
[TBL] [Abstract][Full Text] [Related]
5. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
[TBL] [Abstract][Full Text] [Related]
6. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.
Spierings N; Holt DW; MacPhee IA
Ther Drug Monit; 2013 Jun; 35(3):328-31. PubMed ID: 23666583
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
8. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.
Kurzawski M; Dąbrowska J; Dziewanowski K; Domański L; Perużyńska M; Droździk M
Pharmacogenomics; 2014 Feb; 15(2):179-88. PubMed ID: 24444408
[TBL] [Abstract][Full Text] [Related]
9. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
Ro H; Min SI; Yang J; Moon KC; Kim YS; Kim SJ; Ahn C; Ha J
Ther Drug Monit; 2012 Dec; 34(6):680-5. PubMed ID: 23149441
[TBL] [Abstract][Full Text] [Related]
10. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
Bruckmueller H; Werk AN; Renders L; Feldkamp T; Tepel M; Borst C; Caliebe A; Kunzendorf U; Cascorbi I
Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
[TBL] [Abstract][Full Text] [Related]
11. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
[TBL] [Abstract][Full Text] [Related]
12. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
[TBL] [Abstract][Full Text] [Related]
13. Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.
Ghafari S; Dashti-Khavidaki S; Khatami MR; Ghahremani MH; Seyednejad SA; Beh-Pajooh A
Iran J Kidney Dis; 2019 Nov; 13(6):414-416. PubMed ID: 31880588
[TBL] [Abstract][Full Text] [Related]
14. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
[TBL] [Abstract][Full Text] [Related]
15. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.
de Jonge H; Metalidis C; Naesens M; Lambrechts D; Kuypers DR
Pharmacogenomics; 2011 Sep; 12(9):1281-91. PubMed ID: 21770725
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.
Lesche D; Sigurdardottir V; Setoud R; Oberhänsli M; Carrel T; Fiedler GM; Largiadèr CR; Mohacsi P; Sistonen J
Ther Drug Monit; 2014 Dec; 36(6):710-5. PubMed ID: 24739669
[TBL] [Abstract][Full Text] [Related]
18. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
[TBL] [Abstract][Full Text] [Related]
19. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
[TBL] [Abstract][Full Text] [Related]
20. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]